The Trump administration will let a Biden-era Medicare Part D subsidy program expire at year's end, a move that could raise monthly drug-plan premiums for roughly 25 million older Americans heading into the 2027 coverage year.

The Centers for Medicare and Medicaid Services confirmed the decision in recent days, announcing that the temporary premium-subsidy demonstration launched in 2024 will not continue into 2027. CMS Administrator Mehmet Oz framed the program's end as a necessary correction, The Hill reported, calling the subsidies a taxpayer-funded "bailout" that funneled billions directly to insurance companies.

The announcement lands roughly three months before midterm elections, and just months after congressional Republicans allowed enhanced Affordable Care Act marketplace subsidies to expire, a sequence that hands Democrats a ready-made affordability argument against the GOP.

Oz calls $9.8 billion subsidy a "bailout" for insurers

Oz made the administration's case on social media, posting that "the Biden admin gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies" and calling the arrangement "unacceptable." In a follow-up post, he added:

"We are stabilizing the market, so this bailout is no longer needed. Premiums will go up by less than $10 for most Medicare recipients, with many even seeing LOWER premiums."

A CMS spokesperson echoed that position, telling reporters the subsidies were "only supposed to be temporary" and that insurer plan bids had stabilized enough to justify ending the program. The agency said that among the roughly one-quarter of Medicare beneficiaries enrolled in plans the subsidy covered, more than 85 percent would still have access to a Part D plan that is either lower cost or carries less than a $10-per-month increase next year.

When asked for comment, the White House pointed to Oz's social media posts.

The Government Accountability Office pegged the program's total cost at $9.8 billion across 2025 and 2026. AP News reported that the subsidy cost an estimated $3.6 billion in 2026 alone. At those numbers, the administration's argument is straightforward: the federal government was writing large checks to private insurers to hold premiums down, and now that the market has adjusted, the checks should stop.

That argument has real merit. The Biden administration created the program as a response to premium disruptions caused by the 2022 Inflation Reduction Act, which restructured Medicare Part D by capping out-of-pocket drug spending at $2,000 a year and allowing Medicare to negotiate prices on certain high-cost medications. Those changes shifted costs around the system, and insurers raised their bids. The subsidy was a patch, CMS said at the time it could last "at least three years", not a permanent entitlement.

The administration's decision to end the subsidies fits a broader pattern of unwinding temporary Biden-era spending programs that were designed to look permanent without being funded that way.

KFF analysis: seniors could face a 50 percent premium jump

But the numbers on the other side of the ledger deserve honest attention. Juliette Cubanski, vice president and director of the Program on Medicare Policy at KFF, told The Hill the subsidy had a "meaningful impact" on what seniors actually pay. She laid out the math plainly:

"In 2026, the average premium reduction because of the subsidy program was $16 a month, and that might not sound like a lot, but to put it in context, the average stand-alone drug plan premium this year is $36 a month. So, people might have had to pay nearly 50 percent more for drug coverage this year if the demonstration hadn't been in place."

That $16-per-month gap matters to people on fixed incomes. CMS's own data shows the national average monthly bid for 2027 will rise to $296.05, up from $239.27, a roughly 24 percent increase in the insurer cost estimate. New monthly cost estimates for what enrollees will actually pay won't be released until mid- to late-September, leaving millions of seniors uncertain about their bills heading into open enrollment.

Cubanski acknowledged the administration's broader drug-pricing efforts but noted the tension with this particular move. "President Trump has had a lot of strong rhetoric on drug prices and negotiating deals with manufacturers to lower prices, and they've taken a lot of different steps to try to bring drug prices down," she said. "But it's also true that this move to end these extra premium subsidies for some Medicare drug plans cuts in the other direction because it could translate to higher premium costs for millions of people with Medicare."

The concern is practical, not ideological. As Cubanski put it: "If their prescription drug plan premiums are going to be up for 2027, that just kind of puts more pressure on household budgets that are already being squeezed by higher gas prices and higher housing costs and higher food costs."

Roughly 23 million people were enrolled in stand-alone Medicare Part D drug plans in 2025. Breitbart noted that approximately 25 million Americans with Part D plans could see higher premiums in 2027, making the political stakes difficult to ignore in a midterm year.

Critics call it a choice, not a fiscal necessity

Leslie Dach, founder and chair of the advocacy group Protect Our Care, rejected the administration's cost-saving rationale. "This was a purposeful thing, and all these things are a choice they make," Dach said. He compared the program's annual price tag, which he put at $5 billion, to far larger federal expenditures:

"It'd be like, this costs $5 billion a year, you know, the war is costing us $100 billion, and so this is a choice they've made. It's not fiscal responsibility."

Dach's $5 billion figure is his own characterization and does not perfectly align with the GAO's $9.8 billion total for two years, though the ballpark is similar. His broader point, that the savings are modest relative to overall federal spending, is a standard progressive argument against any entitlement cut, and it should be weighed accordingly. Fiscal discipline has to start somewhere, and temporary programs that quietly become permanent are exactly the kind of spending conservatives have long pledged to end.

Senate Minority Leader Chuck Schumer offered a sharper political attack. "The Trump administration is actively raising prescription drug costs for 25 million seniors," the Washington Examiner reported him saying. He called the move "heartless, cruel, and completely by choice." That language is campaign rhetoric, but the underlying policy question, whether seniors will pay more, is real and will be answered when CMS releases updated premium estimates in September.

Does ending the subsidy push seniors toward Medicare Advantage?

David Lipschutz, co-director of the Center for Medicare Advocacy, raised a structural concern that deserves scrutiny. He argued the subsidy's end "has the impact of favoring enrollment in Medicare Advantage Plans, which some stakeholders are in favor of, and the administration has seemed to express support for."

If stand-alone Part D premiums rise while Medicare Advantage plans, which bundle drug coverage with other benefits, remain subsidized through separate federal payments, some seniors will rationally switch. Lipschutz contended that Medicare Advantage "ends up costing the Medicare program more," a claim that independent analyses have supported for years. If the administration saves $3.6 billion by ending Part D subsidies but drives enrollment toward a costlier program, the net fiscal picture could look worse, not better.

The recent sharp drop in ACA marketplace enrollment after enhanced subsidies expired offers a preview of what happens when temporary premium supports disappear: people leave the market or shift to other coverage, and the political fallout follows.

Lipschutz also predicted how the administration would frame the savings: "I think they will try to look at the savings that the government will have by not going through with this demo and claiming that that's savings to the Medicare program: 'Look at everything we're doing to root out waste, fraud and abuse, and here are some potential savings that we got.'"

That framing would be misleading if the savings are simply shifted costs borne by seniors or redirected into higher Medicare Advantage spending. The administration should be transparent about the full fiscal picture, not just the line item it eliminated.

Administration's drug-pricing agenda complicates the picture

The subsidy decision does not exist in a vacuum. President Trump has promoted the TrumpRx platform and pursued "most-favored-nation" deals with drug companies to bring down prescription costs. Those efforts, if they deliver real price reductions, could offset some of the premium increases seniors face when the Part D subsidy disappears.

But promises and platforms are not the same as lower bills. The administration's credibility on drug affordability will be measured by what seniors actually pay starting in January 2027, and those numbers won't be clear until CMS releases updated premium data in September. Federal prosecutors have also been cracking down on fraud in government health programs, which supports the administration's broader narrative of cleaning up waste. Whether that cleanup extends to ensuring seniors aren't left holding the bag on premiums is a separate question.

Oz's claim that "every Medicare beneficiary still has access to low-cost plans" may be technically accurate. But access to a low-cost plan and keeping the plan you already have at a price you can afford are different things. Seniors who built their budgets around $36-a-month premiums may find 2027 a rude adjustment.

The administration is right that the Biden-era subsidy was always designed as a temporary fix, and that funneling billions to insurers is not a long-term solution. Ending it is defensible policy. But doing it three months before a midterm, without a clear replacement mechanism to cushion the blow, invites exactly the political attack Democrats are already launching, and gives seniors legitimate reason to worry about their next prescription bill.

Conservatives who want smaller government and honest budgeting should welcome the end of a program that was never meant to last. They should also demand that the administration show its work, prove the market really has stabilized, prove the premium increases are as modest as Oz claims, and prove that this isn't just trading one subsidy for higher costs somewhere else. Accountability runs in every direction.